Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Heena Sareen"'
Autor:
Benedicte Grebstad Tune, Heena Sareen, Branka Powter, Smadar Kahana-Edwin, Adam Cooper, Eng-Siew Koh, Cheok S. Lee, Joseph W. Po, Geoff McCowage, Mark Dexter, Lucy Cain, Geraldine O’Neill, Victoria Prior, Jonathan Karpelowsky, Maria Tsoli, Lars O. Baumbusch, David Ziegler, Tara L. Roberts, Paul DeSouza, Therese M. Becker, Yafeng Ma
Publikováno v:
Biomedicines, Vol 11, Iss 11, p 2907 (2023)
Genetic histone variants have been implicated in cancer development and progression. Mutations affecting the histone 3 (H3) family, H3.1 (encoded by HIST1H3B and HIST1H3C) and H3.3 (encoded by H3F3A), are mainly associated with pediatric brain cancer
Externí odkaz:
https://doaj.org/article/444c9199ff6b4d05bfdb45dd6101a100
Publikováno v:
International journal of molecular sciences. 23(16)
Background: Glioblastoma (GBM) is a highly aggressive cancer with poor prognosis that needs better treatment modalities. Moreover, there is a lack of reliable biomarkers to predict the response and outcome of current or newly designed therapies. Whil
Autor:
Branka Powter, Heena Sareen, Mila Sajinovic, Joseph W. Po, Sarah A Jeffreys, Kieran F. Scott, Eng-Siew Koh, Tara L. Roberts, Daniel Brungs, Paul de Souza, Adam Cooper, Therese M. Becker, Joey Yusof Vessey
Publikováno v:
Journal of Cancer Research and Clinical Oncology
The TERT promoter (pTERT) mutations, C228T and C250T, play a significant role in malignant transformation by telomerase activation, oncogenesis and immortalisation of cells. C228T and C250T are emerging as important biomarkers in many cancers includi
Autor:
Joey Yusof Vessey, Renata Bazina, Mathias Jaeger, Celine Garrett, Eng-Siew Koh, Daniel Brungs, David A. Lynch, Mark Sheridan, Therese M. Becker, Adam Cooper, Branka Powter, Tara L. Roberts, Joseph W. Po, Balsam Darwish, Paul de Souza, Heena Sareen, Simon Mckechnie, James M. van Gelder
Publikováno v:
Cancers, Vol 12, Iss 1831, p 1831 (2020)
Cancers
Cancers
Glioblastoma multiforme (GBM) is one of the most lethal primary central nervous system cancers with a median overall survival of only 12–15 months. The best documented treatment is surgical tumor debulking followed by chemoradiation and adjuvant ch